Copenhagen, 2014-05-15 13:00 CEST (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its ragweed sublingual allergy immunotherapy tablet, which is licensed to Merck (known as MSD outside the USA and Canada) for North America, has now been launched in Canada. - See more at: http://www.globenewswire.com/news-release/2014/05/15/636727/0/en/ALK-s-partner-for-North-America-Merck-announces-launch-of-RAGWITEK-in-Canada.html#sthash.Wo5fPgJE.dpuf
Help employers find you! Check out all the jobs and post your resume.
